CBio Brazil (Centro de Biotecnologia do Brasil) is a São Paulo-based biotechnology company pioneering neuroimmunology approaches to treat Alzheimer's disease (AD) and Parkinson's disease (PD). Founded in 2016 by a team of Brazilian neuroscientists and immunologists, CBio Brazil has established itself as a leader in understanding the bidirectional communication between the peripheral immune system and the central nervous system in neurodegenerative disease.
The company's name reflects its mission: "CBio" signifies "Centro de Biotecnologia" (Biotechnology Center), while "Brazil" represents its commitment to advancing Brazilian neuroscience research on the global stage. CBio Brazil operates from state-of-the-art facilities at the Butantan Institute Technology Park in São Paulo, maintaining collaborations with leading international institutions including University of Cambridge, University of Edinburgh, and the University of São Paulo.
Chronic neuroinflammation has emerged as a central pathological feature of both Alzheimer's disease and Parkinson's disease, driving disease progression through mechanisms that extend well beyond the traditional view of neurodegeneration as primarily a neuronal problem[1]. CBio Brazil's therapeutic approach targets this neuroinflammatory component through a sophisticated understanding of how peripheral immune dysfunction influences brain pathology.
The company's founding scientists recognized that neuroinflammation is not merely a consequence of neuronal death but an active driver of disease progression. This insight has led CBio to develop therapies that address the immune system at multiple levels: modulating microglial activation in the brain, regulating peripheral immune cell trafficking across the blood-brain barrier, and normalizing cytokine networks that become dysregulated in neurodegeneration[2].
Microglia, the resident immune cells of the brain, play a dual role in neurodegeneration. In their surveilling state, they perform critical functions in synaptic pruning, brain homeostasis, and pathogen defense. However, in disease states, microglia can adopt a hyperactive, pro-inflammatory phenotype that contributes to neuronal damage through excessive phagocytosis, cytokine release, and induction of reactive astrocyte states[3].
CBio Brazil's research programs target the mechanisms that regulate microglial activation states. The company's scientists have identified key molecular switches that determine whether microglia adopt protective or destructive phenotypes, with particular focus on the TREM2 signaling pathway and its role in microglial survival and function in the aging brain[4].
A critical insight underlying CBio's therapeutic approach is the recognition that peripheral immune cells contribute significantly to neuroinflammation in neurodegenerative diseases. Monocytes, T cells, and other peripheral immune cells can enter the brain in states of inflammation, where they contribute to the neuroinflammatory cascade and exacerbate disease progression[@kiran2022; @bower2020].
This peripheral immune infiltration is mediated by chemokine pathways, particularly the CCL2/CCR2 axis, which CBio Brazil has identified as a key therapeutic target. By modulating this pathway, the company aims to reduce the peripheral immune contribution to neuroinflammation while preserving the beneficial functions of the brain's resident immune cells[5].
CBio Brazil's lead program, CB-101, is a small molecule inhibitor of the CCR2 receptor designed to modulate peripheral immune cell trafficking to the brain. The therapeutic rationale addresses the observation that circulating monocytes can differentiate into brain-resident cells in neurodegenerative conditions, contributing to plaque formation and neuroinflammation[@elkind2021; @lloyd2021].
CB-101 works through selective antagonism of CCR2, a chemokine receptor expressed primarily on monocytes and certain T cell subsets. Under normal conditions, CCR2 mediates monocyte recruitment to sites of inflammation. In Alzheimer's disease, this pathway becomes dysregulated, leading to excessive monocyte infiltration into the brain and contribution to the neuroinflammatory cascade.
By blocking CCR2, CB-101 reduces peripheral monocyte recruitment to the brain while preserving the brain's intrinsic immune surveillance mechanisms. This approach differs from broad immunosuppression by targeting specifically the pathological peripheral immune contribution while leaving protective immune functions intact.
Preclinical studies in 5xFAD transgenic mice demonstrated that CB-101 administration resulted in:
These effects were accompanied by a favorable safety profile in toxicology studies, supporting advancement to clinical development.
CB-101 is currently in Phase I/II clinical development for early Alzheimer's disease:
CBio Brazil's second program targets Parkinson's disease through an immunotherapy approach designed to enhance clearance of pathological alpha-synuclein. Alpha-synuclein aggregation into Lewy bodies is the hallmark pathological feature of PD, and CBio aims to reduce this pathological burden through passive immunization[@mccann2016; @braak2003].
CB-202 is a monoclonal antibody that recognizes a conformation-specific epitope present only on pathological alpha-synuclein aggregates. This selective targeting allows the antibody to bind to Lewy bodies and other pathological alpha-synuclein species while sparing the physiological monomeric form that serves important neuronal functions.
The antibody leverages the brain's natural Fc receptor-mediated transport system to achieve brain penetration, enabling engagement of intracellular and membrane-bound alpha-synuclein aggregates that small molecules cannot access.
CB-202 is in late preclinical development with IND-enabling studies in progress. Key findings from preclinical studies include:
To support patient selection for CB-101 and CB-202 programs, CBio Brazil is developing a companion diagnostic that measures CCL2 levels in cerebrospinal fluid and plasma. CCL2 (also known as MCP-1) is a chemokine that serves as a biomarker of neuroinflammatory activity and may predict which patients are most likely to benefit from immunomodulatory therapy.
This biomarker-driven approach aligns with CBio's precision medicine strategy, enabling selection of patients with elevated neuroinflammation who are most likely to respond to the company's therapeutic candidates.
CBio Brazil maintains a research team of over 40 scientists, including:
The team has established collaborations with leading Brazilian neuroscience centers, including the University of São Paulo, the Butantan Institute, and the Brazilian Academy of Sciences.
CBio Brazil's Phase II trial for CB-101 employs an innovative adaptive design that incorporates:
While founded in Brazil, CBio Brazil has strategically expanded its clinical operations internationally:
CBio Brazil participates in several international research consortia:
CBio Brazil has raised approximately $65 million in funding since founding:
| Round | Year | Amount | Lead Investors |
|---|---|---|---|
| Seed | 2016 | $5M | São Paulo Research Foundation (FAPESP) |
| Series A | 2018 | $18M | 巴西生物技术基金, Qualcomm Ventures |
| Series B | 2021 | $27M | RA Capital, Advent Brazil |
| Series C | 2024 | $15M | Deep Track Capital, Surveyor Capital |
CBio Brazil operates in a competitive space with several companies pursuing neuroimmunology approaches:
| Company | Program | Mechanism | Status |
|---|---|---|---|
| Alector | AL002 | TREM2 agonist | Phase II |
| Cortexyme | COR388 | Gingipain inhibitor | Phase II/III |
| Vir Biotechnology | VIR-2482 | Anti-Aβ antibody | Phase II |
| Prothelia | PRX002 | Anti-α-synuclein antibody | Phase I |
| AC Immune | ACI-35 | Tau vaccine | Phase II |
CBio differentiates through its unique focus on peripheral immune modulation, its CCR2 antagonism approach (versus direct brain targets), and its strong position in the Brazilian and Latin American market.
| Candidate | Target | Indication | Phase | Timeline |
|---|---|---|---|---|
| CB-101 | CCR2 | Early AD | Phase IIa | Data 2027 |
| CB-202 | α-Synuclein | Parkinson's | Preclinical | IND 2026 |
| CB-301 | CCL2 biomarker | Diagnostic | Development | FDA submission 2027 |
CBio Brazil's long-term strategy includes:
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. 2015. ↩︎
Chen Y, et al. Targeting neuroinflammation in Alzheimer's disease: From mechanisms to clinical trials. 2023. ↩︎
Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. 2017. ↩︎
Gutierrez J, et al. TREM2 deficiency results in reduced microglial proliferation and amyloid clearance. 2020. ↩︎
Schwartz M. Neuro-immune interaction: From brain physiology to pathology. 2020. ↩︎